Category: Artios Pharma

  • Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer Therapies

    Shots: Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for joint development & commercialization of the programs Merck has the right to opt into exclusive development & commercialization of compounds on up to 8 targets […]